Engagement — Add-on Due Diligence
Code & Co. provides Tech and Product Due Diligence to the GUS Group prior to its majority investment in LIMS MELOS
Digital networking between laboratories, patients, and B2B partners is becoming a critical factor in the success of contract laboratories. MELOS GmbH (MELOS) is a leading provider of lab software, providing an all-in-one solution for lab system organization. With investment from the GUS Group, MELOS will grow its customer base at home and abroad and continue innovating to provide software supporting the laboratories of the future.
The GUS Group, a leading software provider for laboratory solutions in the DACH region and portfolio company of Bregal Unternehmenskapital, has acquired a majority stake in laboratory systems provider MELOS.
MELOS provides highly scalable network laboratory information systems (LIS) to its clients, which include laboratories and physicians’ associations, national authorities, and DAX-listed corporations. Its portfolio of services also includes the modeling and optimization of processes within digital health and networking projects.
Through the acquisition of MELOS, the GUS Group has expanded its LIS offering, cementing its position as a leading software provider for laboratory solutions in Europe. Adding MELOS to its portfolio of LIS companies enables the GUS Group to offer its laboratory clients a full suite of solutions. The other LIS companies in the group are DORNER GmbH & Co. KG, Blomesystem GmbH and iCD System GmbH,
As part of the GUS Group, MELOS will continue to scale, expanding its customer and partner network in the life and health science industry through professional and organizational synergies. It will operate under the umbrella brand of the GUS Group and benefit from the GUS Group’s support by expanding internationally.
“We are pleased to have advised the GUS Group ahead of its acquisition of MELOS. Adding MELOS’s extensive experience to its current group of LIS companies, we are confident that the GUS Group will expand its market-leading position in the life sciences and processes industries. We are excited to see what is next for these businesses, and how they shape the future of the LIS space,” says Dan Bender, co-founder of Code & Co.
Scope of Work
Code & Co. provided Tech and Product Due Diligence to the GUS Group ahead of its acquisition of MELOS. This included an assessment of MELOS’s architecture, strengths and weaknesses and its growth roadmap and expansion potential. The Tech and Product Due Diligence also included an analysis of MELOS’s flexibility and resilience, as well as the general quality and performance of its software.
Supporting the GUS Group in its investment underlines Code & Co.’s position as a leading Technology and Product Due Diligence provider on biotech and LIS software mandates.
About the GUS Group
The GUS Group develops and implements holistically integrated software solutions for the process industry and logistics. The group's software portfolio supports the entire business cycle - from enterprise resource planning (ERP), supply chain management (SCM), sales management and geomarketing to customer relationship management (CRM), laboratory information management (LIMS) and quality management to finance/controlling, business intelligence and document management.
Since 1988, MELOS has developed into a market leader for laboratory organization software (LIMS & LIS). With the MELOS Digital Network (MDN) platform, a successful portal and interface solution for laboratories, patients, e-health and B2B partners was also created. With 60 employees at three locations in Berlin and Gessertshausen, the company develops modular and at the same time highly scalable network laboratory systems. The service portfolio also includes the modeling and optimization of processes as part of digital health and networking projects. Network laboratories, clinics, laboratory physicians and laboratory communities as well as industrial and special laboratories are among the company's main customers.
About Code & Co.
Code & Co. is an independent advisory firm that specializes in providing modern, actionable Tech and Product Due Diligence for the global alternative investment industry. Our expertise uncovers risks that threaten asset value and opportunities to accelerate growth.